

Cardiac Inflammation Contributes to Changes in the Ex Heart Failure and Normal Ejection Fraction

Circulation: Heart Failure

4, 44-52

DOI: [10.1161/circheartfailure.109.931451](https://doi.org/10.1161/circheartfailure.109.931451)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, e540-3.	1.6	103
3	New Targets to Treat the Structural Remodeling of the Myocardium. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1833-1843.	1.2	147
4	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , 2011, 17, 634-642.	0.7	171
5	Pentraxin 3 as a new biomarker of diastolic dysfunction. <i>International Journal of Cardiology</i> , 2011, 152, 106-107.	0.8	2
6	Involvement of bone morphogenetic protein-binding endothelial regulator in aortic valve stenosis. <i>International Journal of Cardiology</i> , 2011, 152, 107-109.	0.8	0
7	Primary prevention of diastolic dysfunction in the normal heart: The "Eyes Wide Shut" on a statin pleiotropic effect?. <i>Atherosclerosis</i> , 2011, 216, 272-274.	0.4	0
8	Myocardial Basis for Heart Failure. , 2011, , 73-84.		1
9	CD4+CD25+Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. <i>Journal of Hypertension</i> , 2011, 29, 1820-1828.	0.3	69
10	A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: Roles of extracellular signal-regulated kinase 1/2 and nuclear factor- κ B. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 739-746.	0.9	16
11	Diastolic myofilament dysfunction in the failing human heart. <i>Pflügers Archiv European Journal of Physiology</i> , 2011, 462, 155-163.	1.3	45
12	The future diagnosis of heart failure with normal ejection fraction: less imaging, more biomarkers?. <i>European Journal of Heart Failure</i> , 2011, 13, 1043-1045.	2.9	13
13	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. <i>Circulation</i> , 2011, 124, 2082-2093.	1.6	81
14	Transforming Growth Factor- β 2. <i>Circulation: Heart Failure</i> , 2011, 4, 5-7.	1.6	32
15	Effects of Continuous-Flow Versus Pulsatile-Flow Left Ventricular Assist Devices on Myocardial Unloading and Remodeling. <i>Circulation: Heart Failure</i> , 2011, 4, 546-553.	1.6	129
17	Systemic Lupus Erythematosus and Systemic Autoimmune Connective Tissue Disorders behind Recurrent Diastolic Heart Failure. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-6.	3.3	9
18	Protective Function of STAT3 in CVB3-Induced Myocarditis. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-11.	0.5	20
19	Does inflammation trigger fibrosis in hypertrophic cardiomyopathy: a burning question?. <i>Heart</i> , 2012, 98, 965-966.	1.2	7
21	Low-Sodium Dietary Approaches to Stop Hypertension Diet Reduces Blood Pressure, Arterial Stiffness, and Oxidative Stress in Hypertensive Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2012, 60, 1200-1206.	1.3	134

#	ARTICLE	IF	CITATIONS
22	Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling. <i>Journal of Hypertension</i> , 2012, 30, 34-37.	0.3	2
23	Cardiac Intercellular Communication: Are Myocytes and Fibroblasts Fair-Weather Friends?. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 768-782.	1.1	48
24	Interferon- β ablation exacerbates myocardial hypertrophy in diastolic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H587-H596.	1.5	61
25	Molecular and Cellular Basis for Diastolic Dysfunction. <i>Current Heart Failure Reports</i> , 2012, 9, 293-302.	1.3	96
27	Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 37-45.	0.3	24
28	Differences in Biomarkers in Patients With Heart Failure With a Reduced vs a Preserved Left Ventricular Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2012, 28, 62-68.	0.8	24
29	Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor- β mediated fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 9.	3.4	48
30	From Risk Factors to Structural Heart Disease: The Role of Inflammation. <i>Heart Failure Clinics</i> , 2012, 8, 113-123.	1.0	56
31	Inflammatory Cytokines in Heart Failure: Mediators and Markers. <i>Cardiology</i> , 2012, 122, 23-35.	0.6	275
33	Myocardial performance in children with autoimmune hepatitis: Doppler tissue imaging study. <i>European Journal of Pediatrics</i> , 2013, 172, 1511-1519.	1.3	3
34	Attenuation of Monocyte Chemotaxis: A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic Peptide. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 545-557.	1.1	23
35	Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2013, 10, 350-358.	1.3	27
36	Update on Heart Failure with Preserved Ejection Fraction. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 495-502.	0.8	16
37	Myofibroblast-mediated mechanisms of pathological remodelling of the heart. <i>Nature Reviews Cardiology</i> , 2013, 10, 15-26.	6.1	533
38	A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 263-271.	1.2	2,555
39	Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. <i>Basic Research in Cardiology</i> , 2013, 108, 357.	2.5	56
40	Integrating the Myocardial Matrix Into Heart Failure Recognition and Management. <i>Circulation Research</i> , 2013, 113, 725-738.	2.0	67
41	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. <i>Cardiovascular Research</i> , 2013, 99, 111-120.	1.8	113

#	ARTICLE	IF	CITATIONS
43	Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?. <i>Cardiology Research and Practice</i> , 2013, 2013, 1-9.	0.5	14
44	The independent relationship of epicardial adipose tissue with carotid intima-media thickness and endothelial functions. <i>Blood Pressure Monitoring</i> , 2013, 18, 85-93.	0.4	26
45	Diagnosing heart failure with preserved ejection fraction. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 463-474.	1.6	9
46	Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 13-21.	0.8	46
47	Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure. <i>Molecular Medicine</i> , 2014, 20, 221-229.	1.9	114
48	Reactive Oxygen Species (ROS) Signaling in Cardiac Remodeling and Failure. , 2014, , 951-992.		5
49	Crosstalk between fibroblasts and inflammatory cells. <i>Cardiovascular Research</i> , 2014, 102, 258-269.	1.8	419
50	Reversible and irreversible differentiation of cardiac fibroblasts. <i>Cardiovascular Research</i> , 2014, 101, 411-422.	1.8	77
51	Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. <i>Biomarkers in Medicine</i> , 2014, 8, 95-106.	0.6	15
52	New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2014, 11, 436-444.	1.3	78
53	Heart Failure with Preserved Ejection Fraction. , 2014, , 193-203.		2
54	Aortic Stiffness and Interstitial Myocardial Fibrosis by Native T1 Are Independently Associated With Left Ventricular Remodeling in Patients With Dilated Cardiomyopathy. <i>Hypertension</i> , 2014, 64, 762-768.	1.3	50
55	Fibrosis or hypertrophy: let TIMPs decide. <i>Cardiovascular Research</i> , 2014, 103, 196-197.	1.8	8
56	Heart Failure with Preserved Ejection Fraction. <i>Cardiology Clinics</i> , 2014, 32, 151-161.	0.9	13
57	Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 66, 141-156.	0.9	38
58	Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. <i>Basic Research in Cardiology</i> , 2014, 109, 449.	2.5	55
59	Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 776-786.	0.5	20
60	Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 76, 148-157.	0.9	86

#	ARTICLE	IF	CITATIONS
61	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. , 2014, , .		20
62	Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Research in Cardiology, 2014, 109, 428.	2.5	128
63	Heart failure with preserved ejection fraction. Pflugers Archiv European Journal of Physiology, 2014, 466, 1037-1053.	1.3	110
64	Heart Failure With Preserved Ejection Fraction. Circulation Research, 2014, 115, 79-96.	2.0	410
65	Sodium Restriction in Heart Failure: Benefit or Harm?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 286.	0.4	18
66	Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 457-459.	1.2	28
67	Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition. Journal of the American College of Cardiology, 2014, 63, 2734-2741.	1.2	154
68	Heart Failure with Preserved Ejection Fraction: Current Understandings and Challenges. Current Cardiology Reports, 2014, 16, 501.	1.3	45
69	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews, 2014, 19, 681-694.	1.7	137
70	Heart failure with preserved ejection fraction. Expert Review of Cardiovascular Therapy, 2014, 12, 743-750.	0.6	8
71	Causes and Pathophysiology of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 389-398.	1.0	23
72	Stiffness of Left Ventricular Cardiac Fibroblasts Is Associated With Ventricular Dilation in Patients With Recent-Onset Nonischemic and Nonvalvular Cardiomyopathy. Circulation Journal, 2014, 78, 1693-1700.	0.7	9
74	Towards "Eternal Youth"™ of cardiac and skeletal muscle. Global Cardiology Science & Practice, 2015, 2015, 12.	0.3	0
75	Extracellular Matrix Communication and Turnover in Cardiac Physiology and Pathology. , 2015, 5, 687-719.		93
76	Influence of different aetiologies on clinical course and outcome in patients with dilated cardiomyopathy. European Journal of Clinical Investigation, 2015, 45, 906-917.	1.7	6
77	Heart Failure With Preserved Ejection Fraction. Cardiology in Review, 2015, 23, 161-167.	0.6	10
78	Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. Journal of Hypertension, 2015, 33, 1922-1930.	0.3	24
79	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vascular Health and Risk Management, 2015, 11, 283.	1.0	17

#	ARTICLE	IF	CITATIONS
80	Increased Circulating Cathepsin K in Patients with Chronic Heart Failure. PLoS ONE, 2015, 10, e0136093.	1.1	15
81	Inflammation in Heart Failure with Preserved Ejection Fraction. , 2015, , 3-18.		3
82	Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2015, 3, 459-466.	1.9	48
83	A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1407-H1418.	1.5	70
84	Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 550-559.	1.6	643
85	Inflammation in HFrEF: Key or circumstantial?. International Journal of Cardiology, 2015, 189, 259-263.	0.8	51
86	Cardiac Fibrosis and Heart Failure: Cause or Effect?. , 2015, , .		4
87	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	0.6	13
88	A change of heart: oxidative stress in governing muscle function?. Biophysical Reviews, 2015, 7, 321-341.	1.5	28
89	Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. Clinical Research in Cardiology, 2015, 104, 1033-1043.	1.5	15
90	Firefighting in viral myocarditis – Extinguish galectin-3 to control the inflamed heart?. Journal of Molecular and Cellular Cardiology, 2015, 85, 226-228.	0.9	1
91	Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	0
93	Monocyte and macrophage subsets along the continuum to heart failure: Misguided heroes or targetable villains?. Journal of Molecular and Cellular Cardiology, 2015, 89, 136-145.	0.9	49
94	Heart failure with preserved ejection fraction: Defining the function of ROS and NO. Journal of Applied Physiology, 2015, 119, 944-951.	1.2	33
95	Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. American Journal of Physiology - Cell Physiology, 2015, 308, C972-C982.	2.1	46
96	Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 2015, 17, 665-671.	2.9	124
97	Candidate biomarkers in heart failure with reduced and preserved ejection fraction. Biomarkers, 2015, 20, 258-265.	0.9	6
98	Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease. Journal of Cardiovascular Translational Research, 2015, 8, 554-566.	1.1	6

#	ARTICLE	IF	CITATIONS
99	Quantification of diastolic dysfunction via the age dependence of diastolic function â€” Impact of insulin resistance with and without type 2 diabetes. <i>International Journal of Cardiology</i> , 2015, 182, 368-374.	0.8	34
100	Exaggerated Inflammation and Monocytosis Associate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction: Evidence of M2 Macrophage Activation in Disease Pathogenesis. <i>Journal of Cardiac Failure</i> , 2015, 21, 167-177.	0.7	108
101	Association of EGF Receptor and NLRs signaling with Cardiac Inflammation and Fibrosis in Mice Exposed to Fine Particulate Matter. <i>Journal of Biochemical and Molecular Toxicology</i> , 2016, 30, 429-437.	1.4	16
102	Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2016, 1, 207-221.	1.9	44
103	Human Endomyocardial Biopsy Specimen-Derived Stromal Cells Modulate Angiotensin II-Induced Cardiac Remodeling. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1707-1718.	1.6	26
104	Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	2
105	Evolving Concepts on the Basic Mechanisms of Heart Failure. , 2016, , 15-31.		0
106	Understanding heart failure with preserved ejection fraction: where are we today?. <i>Netherlands Heart Journal</i> , 2016, 24, 227-236.	0.3	71
107	Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	40
108	Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. <i>Atherosclerosis</i> , 2016, 251, 25-30.	0.4	47
109	Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome. <i>Circulation: Heart Failure</i> , 2016, 9, e002760.	1.6	62
110	Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation. <i>Hypertension</i> , 2016, 67, 1309-1320.	1.3	35
111	Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2016, 217, 69-79.	0.8	32
112	Turning the Retrospectroscope on Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2016, 22, 1023-1027.	0.7	4
113	Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. <i>International Journal of Cardiology</i> , 2016, 221, 1073-1080.	0.8	33
114	Left atrial changes in early stages of heart failure with preserved ejection fraction. <i>Echocardiography</i> , 2016, 33, 1479-1487.	0.3	18
115	Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 138.	0.7	28
116	Myocardial reverse remodeling: how far can we rewind?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H1402-H1422.	1.5	32

#	ARTICLE	IF	CITATIONS
117	Chronic Heart Failure and Inflammation. <i>Circulation Research</i> , 2016, 119, 159-176.	2.0	475
118	Cardiosphere-Derived Cells Reverse Heart Failure With Preserved Ejection Fraction in Rats by Decreasing Fibrosis and Inflammation. <i>JACC Basic To Translational Science</i> , 2016, 1, 14-28.	1.9	95
119	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2016, 134, 73-90.	1.6	747
120	Extracellular Matrix and Regenerative Therapies from the Cardiac Perspective. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 202-213.	5.6	16
121	Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. <i>Heart</i> , 2016, 102, 257-259.	1.2	59
122	The TGF- β 2 pathway mediates doxorubicin effects on cardiac endothelial cells. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 90, 129-138.	0.9	27
123	A Central Role for Monocyte-Platelet Interactions in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 245-261.	1.0	22
124	Emerging role of liver X receptors in cardiac pathophysiology and heart failure. <i>Basic Research in Cardiology</i> , 2016, 111, 3.	2.5	54
125	The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. <i>Netherlands Heart Journal</i> , 2016, 24, 259-267.	0.3	43
126	Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?. <i>Netherlands Heart Journal</i> , 2016, 24, 268-274.	0.3	47
127	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. <i>Heart</i> , 2016, 102, 320-330.	1.2	29
128	Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. <i>Heart and Vessels</i> , 2016, 31, 1361-1369.	0.5	9
129	Atrial Fibrillation Begets Heart Failure and Vice Versa. <i>Circulation</i> , 2016, 133, 484-492.	1.6	561
130	Cardiomyocyte Ca^{2+} dynamics: clinical perspectives. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 65-77.	0.4	11
131	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 312-324.	1.9	390
132	The Human Microcirculation. <i>Circulation Research</i> , 2016, 118, 157-172.	2.0	222
133	Monocyte and macrophage contributions to cardiac remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 149-155.	0.9	210
134	Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions. <i>FASEB Journal</i> , 2016, 30, 688-701.	0.2	39

#	ARTICLE	IF	CITATIONS
135	A Review of the DASH Diet as an Optimal Dietary Plan for Symptomatic Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 548-554.	1.6	29
136	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
137	Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017, 19, 499-501.	2.9	8
138	Intercellular Signalling Cross-Talk: To Kill, To Heal and To Rejuvenate. <i>Heart Lung and Circulation</i> , 2017, 26, 648-659.	0.2	24
139	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 399-409.	0.9	20
140	Galectin-3 Levels Are Elevated and Predictive of Mortality in Pulmonary Hypertension. <i>Heart Lung and Circulation</i> , 2017, 26, 1208-1215.	0.2	31
141	The Role of Inflammation in Cardiovascular Outcome. <i>Current Atherosclerosis Reports</i> , 2017, 19, 11.	2.0	101
142	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2017, 113, 906-914.	1.8	20
143	Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). <i>Current Heart Failure Reports</i> , 2017, 14, 187-196.	1.3	5
144	Insights into cardiac involvement in ankylosing spondylitis from cardiovascular magnetic resonance. <i>Heart</i> , 2017, 103, 745-752.	1.2	26
145	Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H392-H407.	1.5	49
147	Coronary Microcirculatory Dysfunction in Human Cardiomyopathies. <i>Cardiology in Review</i> , 2017, 25, 165-178.	0.6	12
148	Diagnostic and Prognostic Value of CMR T 1 -Mapping in Patients With Heart Failure and Preserved Ejection Fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 848-855.	0.4	6
149	Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. <i>British Journal of Pharmacology</i> , 2017, 174, 4070-4086.	2.7	58
151	ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 103, 74-92.	0.9	56
152	Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance. <i>Stem Cells Translational Medicine</i> , 2017, 6, 2135-2145.	1.6	28
153	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2186-2200.	1.2	159
154	Human heart failure with preserved ejection versus feline cardiomyopathy: what can we learn from both veterinary and human medicine?. <i>Heart Failure Reviews</i> , 2017, 22, 783-794.	1.7	4

#	ARTICLE	IF	CITATIONS
155	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	60
157	Inspiration from heart development: Biomimetic development of functional human cardiac organoids. <i>Biomaterials</i> , 2017, 142, 112-123.	5.7	109
158	Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report. <i>ESC Heart Failure</i> , 2017, 4, 645-648.	1.4	8
159	Role of cardiac inflammation in right ventricular failure. <i>Cardiovascular Research</i> , 2017, 113, 1441-1452.	1.8	58
160	Where Does Inflammation Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 84.	1.3	32
161	Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3-Induced Myocarditis. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	63
162	MiRNA Deregulation in Cardiac Aging and Associated Disorders. <i>International Review of Cell and Molecular Biology</i> , 2017, 334, 207-263.	1.6	23
163	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. <i>Current Cardiology Reports</i> , 2017, 19, 70.	1.3	24
164	Inflammation – Cause or Consequence of Heart Failure or Both?. <i>Current Heart Failure Reports</i> , 2017, 14, 251-265.	1.3	324
165	Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis. <i>Basic Research in Cardiology</i> , 2017, 112, 34.	2.5	26
166	Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. <i>Cardiology</i> , 2017, 136, 192-203.	0.6	16
167	Periodontitis and myocardial hypertrophy. <i>Hypertension Research</i> , 2017, 40, 324-328.	1.5	11
168	Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice. <i>Scientific Reports</i> , 2017, 7, 17045.	1.6	9
169	Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice. <i>Scientific Reports</i> , 2017, 7, 18039.	1.6	8
170	The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis. <i>Frontiers in Physiology</i> , 2017, 8, 777.	1.3	162
171	Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. <i>Frontiers in Endocrinology</i> , 2017, 8, 160.	1.5	50
172	Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-17.	0.9	19
173	CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis. <i>PLoS ONE</i> , 2017, 12, e0182643.	1.1	28

#	ARTICLE	IF	CITATIONS
174	Biomarkers and echocardiography for evaluating the improvement of the ventricular diastolic function after surgical relief of hydronephrosis. PLoS ONE, 2017, 12, e0188597.	1.1	5
175	Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-17.	1.9	43
176	Mitochondrial DNA as an inflammatory mediator in cardiovascular diseases. Biochemical Journal, 2018, 475, 839-852.	1.7	101
177	MicroRNAs in Peripheral Mononuclear Cells as Potential Biomarkers in Hypertensive Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Hypertension, 2018, 31, 651-657.	1.0	15
178	Role of Monocytes in Heart Failure and Atrial Fibrillation. Journal of the American Heart Association, 2018, 7, .	1.6	72
179	Canonical PI3K β signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. Nature Communications, 2018, 9, 1513.	5.8	19
180	Cardiac (myo)fibroblasts modulate the migration of monocyte subsets. Scientific Reports, 2018, 8, 5575.	1.6	26
181	Pro-inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, .	1.6	45
182	Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovascular Research, 2018, 114, 954-964.	1.8	148
183	Cardiac macrophages promote diastolic dysfunction. Journal of Experimental Medicine, 2018, 215, 423-440.	4.2	314
184	Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?. Cardiovascular Research, 2018, 114, 210-225.	1.8	67
185	Obesity and heart failure with preserved ejection fraction: A growing problem. Trends in Cardiovascular Medicine, 2018, 28, 322-327.	2.3	17
186	Serum "glucocorticoid-regulated kinase 1 contributes to mechanical stretch-induced inflammatory responses in cardiac fibroblasts. Molecular and Cellular Biochemistry, 2018, 445, 67-78.	1.4	12
187	Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC: Heart Failure, 2018, 6, 1-7.	1.9	90
188	Sex and Gender Differences in Cardiovascular Disease. , 2018, , 351-367.		0
189	Comparison of MOLLI, shMOLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction. European Heart Journal Cardiovascular Imaging, 2018, 19, 768-776.	0.5	56
190	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. Journal of the American Society of Hypertension, 2018, 12, 438-447.e4.	2.3	20
191	Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. Clinical Reviews in Allergy and Immunology, 2018, 55, 254-270.	2.9	5

#	ARTICLE	IF	CITATIONS
192	Heart failure with preserved ejection fraction: current management and future strategies. <i>Clinical Research in Cardiology</i> , 2018, 107, 1-19.	1.5	64
193	Cardiac metabolism – A promising therapeutic target for heart failure. , 2018, 182, 95-114.		64
194	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , 2018, 20, 460-470.	2.9	29
195	Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis. <i>Texas Heart Institute Journal</i> , 2018, 45, 151-161.	0.1	85
196	Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients. <i>Journal of Clinical Medicine</i> , 2018, 7, 427.	1.0	21
197	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3719.	1.8	15
198	Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2882.	1.8	11
199	Targeted HFpEF therapy based on matchmaking of human and animal models. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H1670-H1683.	1.5	16
200	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , 2018, 72, 549-558.	1.3	123
201	Effects of spironolactone in heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2018, 97, e11942.	0.4	14
202	Myocardial expression of the anaphylatoxin receptor C3aR is associated with cardiac inflammation and prognosis in patients with non-ischaemic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 846-857.	1.4	9
203	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1033-H1042.	1.5	101
204	Macrophages and Cardiovascular Health. <i>Physiological Reviews</i> , 2018, 98, 2523-2569.	18.1	79
205	Autophagy and oxidative stress in non-communicable diseases: A matter of the inflammatory state?. <i>Free Radical Biology and Medicine</i> , 2018, 124, 61-78.	1.3	61
206	Progress in heart failure treatment in Germany. <i>Clinical Research in Cardiology</i> , 2018, 107, 105-113.	1.5	9
207	MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease. <i>Open Medicine (Poland)</i> , 2018, 13, 237-246.	0.6	20
208	Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H934-H949.	1.5	112
209	Truncations of the titin Z-disc predispose to a heart failure with preserved ejection phenotype in the context of pressure overload. <i>PLoS ONE</i> , 2018, 13, e0201498.	1.1	6

#	ARTICLE	IF	CITATIONS
210	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. <i>European Journal of Heart Failure</i> , 2018, 20, 1385-1391.	2.9	38
211	Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 579-589.	0.6	38
212	High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. <i>PLoS ONE</i> , 2018, 13, e0201836.	1.1	78
213	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	1.2	91
214	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	1.0	250
215	<i>Silybum marianum</i> provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis. <i>International Journal of Cardiology</i> , 2018, 270, 28-35.	0.8	22
216	A Global Assessment of Circulating Prolysin Oxidase in Nonischemic Patients With Garden-variety Heart Failure With Preserved Ejection Fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 407-415.	0.4	0
217	Flow-mediated dilation and heart failure: a review with implications to physical rehabilitation. <i>Heart Failure Reviews</i> , 2019, 24, 69-80.	1.7	21
218	Xiao-Qing-Long Tang Prevents Cardiomyocyte Hypertrophy, Fibrosis, and the Development of Heart Failure with Preserved Ejection Fraction in Rats by Modulating the Composition of the Gut Microbiota. <i>BioMed Research International</i> , 2019, 2019, 1-17.	0.9	15
219	Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits. <i>PLoS ONE</i> , 2019, 14, e0220707.	1.1	10
220	Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1592.	2.2	92
221	Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. <i>Disease Markers</i> , 2019, 2019, 1-14.	0.6	41
222	Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 219.	0.7	13
223	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2019, 10, 1347.	1.3	81
224	Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction. <i>Theranostics</i> , 2019, 9, 6550-6567.	4.6	61
225	Biomechanical assessment of remote and postinfarction scar remodeling following myocardial infarction. <i>Scientific Reports</i> , 2019, 9, 16744.	1.6	17
226	Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7505-7516.	1.6	26
227	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	1.0	944

#	ARTICLE	IF	CITATIONS
228	Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. <i>Frontiers in Physiology</i> , 2019, 10, 1108.	1.3	49
229	Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. <i>JACC Basic To Translational Science</i> , 2019, 4, 575-591.	1.9	125
230	Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts. <i>Biomolecules</i> , 2019, 9, 38.	1.8	20
231	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. <i>Trends in Molecular Medicine</i> , 2019, 25, 328-340.	3.5	51
232	Roles of the Mesenchymal Stromal/Stem Cell Marker Meclin in Cardiac Tissue Repair and the Development of Diastolic Dysfunction. <i>Circulation Research</i> , 2019, 125, 414-430.	2.0	47
233	Left atrial microvascular endothelial dysfunction, myocardial inflammation and fibrosis after selective insular cortex ischemic stroke. <i>International Journal of Cardiology</i> , 2019, 292, 148-155.	0.8	32
234	Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2267-2282.	1.2	119
235	Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. <i>Frontiers in Physiology</i> , 2019, 10, 638.	1.3	87
236	Inflammatory and Molecular Pathways in Heart Failure—Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2322.	1.8	61
237	Sex Specific Mechanisms of Myocardial Hypertrophy and Heart Failure. , 2019, , 291-318.		1
238	Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. <i>European Heart Journal</i> , 2019, 40, 3318-3332.	1.0	39
239	Cardiovascular inflammation: RNA takes the lead. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 247-256.	0.9	17
240	Hypoxia-inducible factor 1 α (HIF1 α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction. <i>Obesity Reviews</i> , 2019, 20, 701-712.	3.1	57
241	Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. <i>Ageing Research Reviews</i> , 2019, 56, 100980.	5.0	107
242	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019, 4, 924-937.	1.9	24
243	Kaempferol Prevents Against Ang II-induced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 326-335.	0.8	45
244	Beneficial Prognostic Effects of Statins in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients—HFpEF as a Manifestation of Systemic Disease. <i>Circulation Journal</i> , 2019, 83, 277-278.	0.7	2
245	Myocardial Microvascular Dysfunction in Rheumatoid Arthritis. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e007495.	1.3	36

#	ARTICLE	IF	CITATIONS
246	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 41-63.	4.2	23
247	Aging, MicroRNAs, and Heart Failure. <i>Current Problems in Cardiology</i> , 2020, 45, 100406.	1.1	16
248	Alterations in Ventricular Function. , 2020, , 151-165.e3.		0
249	Myocardial Basis for Heart Failure. , 2020, , 62-75.e7.		0
250	Heart failure with preserved ejection fraction: the missing pieces in diagnostic imaging. <i>Heart Failure Reviews</i> , 2020, 25, 305-319.	1.7	9
251	Sex-Related Differences in the Extent of Myocardial Fibrosis in Patients With Aortic Valve Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 699-711.	2.3	67
252	Reappraisal of Inflammatory Biomarkers in Heart Failure. <i>Current Heart Failure Reports</i> , 2020, 17, 9-19.	1.3	21
253	Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from) Tj ETQq1 1 0.784314 rgBT /Ovele	0.7	27
254	Early cardiac dysfunction in children and young adults with perinatally acquired HIV. <i>Aids</i> , 2020, 34, 539-548.	1.0	6
255	Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 705-716.	0.7	3
256	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117
257	Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. <i>JACC: Heart Failure</i> , 2020, 8, 712-724.	1.9	138
258	Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Journal of the American Heart Association</i> , 2020, 9, e019390.	1.6	30
259	Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease. <i>Frontiers in Physiology</i> , 2020, 11, 793.	1.3	61
260	Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 394.	0.7	16
261	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	3.3	104
262	Coronary Microvascular Dysfunction. <i>Journal of Clinical Medicine</i> , 2020, 9, 2880.	1.0	167
263	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. <i>ESC Heart Failure</i> , 2020, 7, 1676-1687.	1.4	9

#	ARTICLE	IF	CITATIONS
264	Physical activity and exercise training in heart failure with preserved ejection fraction: gathering evidence from clinical and pre-clinical studies. <i>Heart Failure Reviews</i> , 2022, 27, 573-586.	1.7	11
265	Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function. <i>Cardiovascular Research</i> , 2020, 116, 1850-1862.	1.8	22
266	Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 689-712.	2.5	22
267	Inflammation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1324-1340.	1.2	273
268	Research Priorities for Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 1001-1026.	1.6	239
269	Associations of inflammatory markers with impaired left ventricular diastolic and systolic function in collagen-induced arthritis. <i>PLoS ONE</i> , 2020, 15, e0230657.	1.1	16
270	Distinctive patterns of inflammation across the heart failure syndrome. <i>Heart Failure Reviews</i> , 2021, 26, 1333-1344.	1.7	32
271	How to diagnose heart failure with preserved ejection fraction: the HFA "PEFF" diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	2.9	193
272	Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation. <i>Thrombosis Research</i> , 2020, 195, 16-20.	0.8	5
273	Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 494-502.	0.6	27
274	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. <i>Basic Research in Cardiology</i> , 2020, 115, 39.	2.5	77
275	Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. <i>Heart Rhythm</i> , 2020, 17, 1025-1033.	0.3	34
276	Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction. <i>Life Sciences</i> , 2020, 247, 117440.	2.0	23
277	The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	6
278	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). <i>American Heart Journal</i> , 2020, 222, 183-190.	1.2	14
279	Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. <i>Cells</i> , 2020, 9, 242.	1.8	176
280	Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-20.	1.9	11
281	Serum Albumin Is a Marker of Myocardial Fibrosis, Adverse Pulsatile Aortic Hemodynamics, and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2020, 9, e014716.	1.6	33

#	ARTICLE	IF	CITATIONS
282	Metabolic inflammation in heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 423-434.	1.8	102
283	Imaging Interstitial Fibrosis, Left Ventricular Remodeling, and Function in Stage A and B Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1038-1052.	2.3	42
284	Silenced SOX2 ^{OT} alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR-2355 ^{3p} . <i>Immunity, Inflammation and Disease</i> , 2021, 9, 255-264.	1.3	14
285	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <i>Postgraduate Medicine</i> , 2021, 133, 125-139.	0.9	8
286	Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2021, 143, 120-134.	1.6	123
287	Sweat the small stuff: The human microvasculature and heart disease. <i>Microcirculation</i> , 2021, 28, e12658.	1.0	4
288	Prognostic significance of present atrial fibrillation on a single office electrocardiogram in patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2021, 289, 395-403.	2.7	0
289	Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. <i>Lancet Rheumatology</i> , The, 2021, 3, e58-e70.	2.2	121
290	Cellular and molecular pathobiology of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2021, 18, 400-423.	6.1	198
291	Future Therapies in HFpEF. , 2021, , 489-494.		0
293	Platelet Activity and Its Correlation with Inflammation and Cell Count Readings in Chronic Heart Failure Patients with Reduced Ejection Fraction. <i>Medicina (Lithuania)</i> , 2021, 57, 176.	0.8	4
294	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2021, 18, 479-498.	6.1	128
295	Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 626375.	1.6	11
296	Excess TGF- β 1 Drives Cardiac Mesenchymal Stromal Cells to a Pro-Fibrotic Commitment in Arrhythmogenic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2673.	1.8	17
297	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	2.2	26
298	Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction. <i>European Cardiology Review</i> , 2021, 16, e13.	0.7	26
299	Left Atrial Remodeling Mechanisms Associated with Atrial Fibrillation. <i>Cardiovascular Engineering and Technology</i> , 2021, 12, 361-372.	0.7	23
300	P2X7 Receptor-Mediated Inflammation in Cardiovascular Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 654425.	1.6	19

#	ARTICLE	IF	CITATIONS
301	Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 678530.	1.1	6
302	Vascularisation of pluripotent stem cell-derived myocardium: biomechanical insights for physiological relevance in cardiac tissue engineering. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1117-1136.	1.3	7
303	Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. <i>Cells</i> , 2021, 10, 881.	1.8	29
304	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. <i>Clinical Science</i> , 2021, 135, 991-1007.	1.8	18
305	The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential. <i>Genes and Diseases</i> , 2022, 9, 959-972.	1.5	9
306	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 632728.	1.1	4
307	Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease. <i>Respiratory Investigation</i> , 2021, 59, 342-349.	0.9	7
308	Sex differences in the longitudinal relationship of low-grade inflammation and echocardiographic measures in the Hoorn and FLEMENGHO Study. <i>PLoS ONE</i> , 2021, 16, e0251148.	1.1	2
309	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021, 42, 1940-1958.	1.0	34
310	Splenic Volume Index Determined Using Computed Tomography upon Admission Is Associated with Readmission for Heart Failure Among Patients with Acute Decompensated Heart Failure. <i>International Heart Journal</i> , 2021, 62, 584-591.	0.5	4
311	The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. <i>ESC Heart Failure</i> , 2021, 8, 2991-3001.	1.4	20
312	Proteome analysis demonstrates involvement of endoplasmic reticulum stress response in human myocardium with subclinical left ventricular diastolic dysfunction. <i>Geriatrics and Gerontology International</i> , 2021, 21, 577-583.	0.7	3
313	Diagnosis of heart failure with preserved ejection fraction. Not seeing the forest for the trees or a step to precision medicine?. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2497-2499.	0.7	0
314	Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021120.	1.6	10
315	Effects of extended pharmacological disruption of zebrafish embryonic heart biomechanical environment on cardiac function, morphology, and gene expression. <i>Developmental Dynamics</i> , 2021, 250, 1759-1777.	0.8	7
316	High Neutrophil to Lymphocyte Ratio and Its Gene Signatures Correlate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614757.	1.1	19
317	Derivation of an electronic frailty index for predicting short-term mortality in heart failure: a machine learning approach. <i>ESC Heart Failure</i> , 2021, 8, 2837-2845.	1.4	21
318	Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2647-2666.	1.6	62

#	ARTICLE	IF	CITATIONS
319	Impact of cardiac fibrosis and collagens on right ventricular failure and acute kidney injury in patients after continuous-flow left ventricular assist devices. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, , .	0.5	1
320	Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1633-1644.	2.9	26
321	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 1382-1392.	0.7	3
322	Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659666.	1.8	19
323	Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. <i>Scientific Reports</i> , 2021, 11, 14989.	1.6	4
324	Renal Dysfunction and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 357-367.	1.0	9
325	Unveiling the role of exercise training in targeting the inflammatory paradigm of heart failure with preserved ejection fraction: a narrative review. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	3
326	Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	3
327	ANTAGONIZING THE CX3CR1 RECEPTOR MARKEDLY REDUCES DEVELOPMENT OF CARDIAC HYPERTROPHY AFTER TRANSVERSE AORTIC CONSTRICTION IN MICE. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, 792-801.	0.8	4
328	Multiple roles of cardiac macrophages in heart homeostasis and failure. <i>Heart Failure Reviews</i> , 2022, 27, 1413-1430.	1.7	24
329	Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 695952.	1.1	13
330	Chronic low-grade inflammation in heart failure with preserved ejection fraction. <i>Aging Cell</i> , 2021, 20, e13453.	3.0	33
331	Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Pharmacology</i> , 2021, 12, 724320.	1.6	2
332	Potential of valsartan+sacubitril therapy in hypertensive heart disease. <i>Russian Journal of Cardiology</i> , 2021, 26, 4568.	0.4	1
333	VCAM-1 as a predictor biomarker in cardiovascular disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166170.	1.8	78
334	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldoà€œDHF Trial. <i>Pharmacotherapy</i> , 2021, , .	1.2	7
335	Subclinical Heart Remodeling and Dysfunction in Relation to Peripheral Endothelial Dysfunction: a general population study. <i>Microcirculation</i> , 2021, 28, e12731.	1.0	1
336	Predominance of Heart Failure With Preserved Ejection Fraction in Postmenopausal Women: Intra- and Extra-Cardiomyocyte Maladaptive Alterations Scaffolded by Estrogen Deficiency. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 685996.	1.8	13

#	ARTICLE	IF	CITATIONS
337	Therapeutic Potential of HDL in Cardioprotection and Tissue Repair. Handbook of Experimental Pharmacology, 2015, 224, 527-565.	0.9	39
338	Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovascular Research, 2020, 116, 806-816.	1.8	102
339	Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight, 2017, 2, .	2.3	55
340	Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. JCI Insight, 2018, 3, .	2.3	27
341	Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. Journal of Geriatric Cardiology, 2015, 12, 1-10.	0.2	27
342	Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction. PLoS ONE, 2013, 8, e68893.	1.1	72
343	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS ONE, 2016, 11, e0167582.	1.1	22
344	Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2454.	0.4	6
345	The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction. Current Pharmaceutical Design, 2019, 24, 5525-5527.	0.9	2
346	The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction. Acta Naturae, 2020, 12, 40-51.	1.7	10
347	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. Korean Journal of Internal Medicine, 2016, 31, 1-14.	0.7	13
348	Myocardial T1 mapping: modalities and clinical applications. Cardiovascular Diagnosis and Therapy, 2014, 4, 126-37.	0.7	66
349	Prevalence of Obstructive Coronary Artery Disease in Ambulatory Patients with Stable Angina Pectoris. Journal of Clinical & Experimental Cardiology, 2015, 06, .	0.0	2
350	Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiology Journal, 2016, 23, 591-598.	0.5	10
351	Left Ventricular Diastolic Dysfunction in Ischemic Stroke: Functional and Vascular Outcomes. Journal of Stroke, 2016, 18, 195-202.	1.4	29
352	Lipotoxicity: a driver of heart failure with preserved ejection fraction?. Clinical Science, 2021, 135, 2265-2283.	1.8	22
353	Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure. Circulation Research, 2021, 129, 1125-1140.	2.0	16
354	Ageing and Diastolic Dysfunction: The Interplay of Inflammation and Extracellular Matrix Regulation. , 2014, , 183-198.		0

#	ARTICLE	IF	CITATIONS
355	Impact of Comorbidities on Myocardial Remodeling and Dysfunction In Heart Failure with Preserved Ejection Fraction. SOJ Pharmacy & Pharmaceutical Sciences, 0, , .	0.1	1
356	Remodelling of the Cardiac Extracellular Matrix: Role of Collagen Degradation and Accumulation in Pathogenesis of Heart Failure. , 2015, , 219-235.		0
357	Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: Clinical Relevance, Management, and Future Directions. Advances in Pulmonary Hypertension, 2015, 14, 88-94.	0.1	0
358	Diastolic dysfunction in patients with ischemic heart disease and effectiveness myocardial revascularization. LÃ¼ki UkraÃ¼ni, 2016, .	0.0	0
359	Acute Heart Failure Syndromes. , 2017, , 81-162.		0
360	Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). , 2017, , 273-339.		0
361	Heart Failure in Women: Is There a Typical Female Type?. , 2017, , 107-116.		0
362	Proinflammatory cytokines and signaling pathways in peripheral blood mononuclear cells in patients with coronary artery disease. Klinicheskaia Meditsina, 2017, 95, 238-244.	0.2	6
363	OBSOLETE: Sex and Gender Differences in Cardiovascular Disease. , 2018, , .		0
364	Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction.. Klinicheskaia Meditsina, 2018, 95, 1070-1076.	0.2	1
365	How does the Extracellular Matrix Change in the Setting of Heart Failure?. International Journal of Medical Students, 2018, 6, 102-109.	0.2	0
366	Un anÃ¼lisis general de la prolisil-oxidasa circulante en pacientes no isquÃ©micos con una insuficiencia cardiaca comÃ¼n con fracciÃ³n de eyecciÃ³n conservada. Revista Espanola De CardiologÃ­a, 2019, 72, 407-415.	0.6	0
367	Cardiomyopathies - The special entity of myocarditis and inflammatory cardiomyopathy. Journal of Cardiology and Cardiovascular Medicine, 2019, 4, 053-070.	0.1	3
368	The Research Progress of Cardiac Implantable Electronic Device-Identified Atrial Fibrillation. Advances in Clinical Medicine, 2020, 10, 222-231.	0.0	0
370	Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives. American Journal of Cardiovascular Disease, 2019, 9, 91-108.	0.5	7
371	Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. Journal of Geriatric Cardiology, 2021, 18, 376-397.	0.2	1
372	Microvascular Ageing Links Metabolic Disease to Age-Related Disorders: The Role of Oxidative Stress and Inflammation in Promoting Microvascular Dysfunction. Journal of Cardiovascular Pharmacology, 2021, 78, S78-S87.	0.8	17
373	Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. Frontiers in Endocrinology, 2021, 12, 770815.	1.5	21

#	ARTICLE	IF	CITATIONS
374	Viral Myocarditisâ€”From Pathophysiology to Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 5240.	1.0	28
375	Nicotinicâ€œacid derivative BGPâ€œ15 improves diastolic function in a rabbit model of atherosclerotic cardiomyopathy. <i>British Journal of Pharmacology</i> , 2022, 179, 2240-2258.	2.7	3
376	Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 749-757.	0.9	7
377	Associations between galectin-1, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction. <i>Journal of Cardiology</i> , 2021, , .	0.8	1
378	Cytokine-Mediated Alterations of Human Cardiac Fibroblastâ€œs Secretome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12262.	1.8	8
379	Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. <i>PLoS ONE</i> , 2022, 17, e0262479.	1.1	1
380	Quantifying Risk Factors for Atrial Fibrillation: Retrospective Review of a Large Electronic Patient Database. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2365.	0.5	0
381	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. <i>Biomolecules</i> , 2022, 12, 176.	1.8	20
382	CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction. <i>International Journal of Biological Sciences</i> , 2022, 18, 1271-1287.	2.6	14
383	Phenotypic and Functional Heterogeneity of Monocyte Subsets in Chronic Heart Failure Patients. <i>Biology</i> , 2022, 11, 195.	1.3	1
384	Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e023582.	1.6	40
385	CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells. <i>Circulation</i> , 2022, 145, 765-782.	1.6	42
386	The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction. <i>Biomolecules</i> , 2022, 12, 278.	1.8	14
387	Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 602.	1.4	21
388	The Cardiomyocyte in Heart Failure with Preserved Ejection Fractionâ€œ”Victim of Its Environment?. <i>Cells</i> , 2022, 11, 867.	1.8	1
389	Pathophysiologic Basis and Diagnostic Approaches for Ischemia With Non-obstructive Coronary Arteries: A Literature Review. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 731059.	1.1	8
390	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
391	Coronary flow reserve in patients with heart failure with preserved ejection fraction. <i>Russian Journal of Cardiology</i> , 2022, 27, 4743.	0.4	5

#	ARTICLE	IF	CITATIONS
392	Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 1801-1811.	1.4	2
393	Cardio-Rheumatology. Medical Clinics of North America, 2022, 106, 349-363.	1.1	3
394	Targeting the vasculature in cardiometabolic disease. Journal of Clinical Investigation, 2022, 132, .	3.9	18
396	Alpha-Adrenoceptors activate NLRP3 inflammasome through downregulation of Kir2.1 in cardiac inflammation. Experimental Physiology, 2022, , .	0.9	2
397	Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. Journal of Molecular and Cellular Cardiology, 2022, 167, 17-31.	0.9	52
401	Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 1346-1356.	2.9	26
402	Correlation Studies of Serum 25-(OH)D, FIB, MPV/PLT Levels and Chronic Heart Failure. Advances in Clinical Medicine, 2022, 12, 4122-4126.	0.0	0
403	Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models. JACC Basic To Translational Science, 2022, 7, 844-857.	1.9	11
404	R�le des int�grines dans la fibrose cardiaque. Medecine/Sciences, 2022, 38, 438-444.	0.0	0
405	Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. , 2022, 237, 108228.		9
406	Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction. Biomedicine and Pharmacotherapy, 2022, 153, 113326.	2.5	4
407	The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	3
408	Naltrexone-Induced Cardiac Function Improvement is Associated With an Attenuated Inflammatory Response and Lipid Peroxidation in Volume Overloaded Rats. Frontiers in Pharmacology, 0, 13, .	1.6	2
409	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 0, 13, .	1.3	13
410	Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility. Cardiovascular Drugs and Therapy, 2023, 37, 379-399.	1.3	2
411	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. CJC Open, 2022, 4, 959-969.	0.7	3
413	Obesity, inflammation, and cardiovascular disorders. , 2023, , 119-130.		0
414	Sex differences and related estrogenic effects in heart failure with preserved ejection fraction. Heart Failure Reviews, 2023, 28, 937-948.	1.7	5

#	ARTICLE	IF	CITATIONS
415	Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction. <i>Cardiology Clinics</i> , 2022, 40, 397-413.	0.9	6
416	Notch1 signaling activation alleviates coronary microvascular dysfunction through histone modification of Nrg-1 via the interaction between NICD and GCN5. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, 28, 124-135.	2.2	2
417	Angiotensin, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. <i>European Journal of Internal Medicine</i> , 2022, 106, 111-119.	1.0	6
419	AMPK/Sirt1-mediated inflammation is positively correlated with myocardial fibrosis during ageing. <i>Acta Cardiologica</i> , 2022, 77, 826-835.	0.3	6
420	Neuregulin-1 β , Biomarkers of Inflammation and Myocardial Fibrosis in Heart Failure Patients. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 522-529.	0.3	3
421	Heart Failure in Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 67-79.	0.8	1
422	PCSK9: A emerging participant in heart failure. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114106.	2.5	11
423	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46.		9
424	Disturbed Sleep is Not Good for the Heart: A Narrative Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	1
425	Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
426	Cardiac metabolism in HFpEF: from fuel to signalling. <i>Cardiovascular Research</i> , 2023, 118, 3556-3575.	1.8	20
427	Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
428	Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
429	Pathogenic roles of neutrophil-derived alarmins (S100A8/A9) in heart failure: From molecular mechanisms to therapeutic insights. <i>British Journal of Pharmacology</i> , 2023, 180, 573-588.	2.7	6
431	Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context. <i>Circulation</i> , 2023, 147, 83-100.	1.6	6
432	Heart Failure With Preserved Ejection Fraction: Will Cardiac Magnetic Imaging Impact on Diagnosis, Treatment, and Outcomes?. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	0
433	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside and Back. <i>Biomedicine</i> , 2023, 11, 70.	1.4	1
434	FOXO3A acts as immune response modulator in human virus-negative inflammatory cardiomyopathy. <i>Heart</i> , 2023, 109, 846-856.	1.2	0

#	ARTICLE	IF	CITATIONS
435	Monocyte-to-lymphocyte ratio predicts mortality and cardiovascular mortality in the general population. <i>International Journal of Cardiology</i> , 2023, 379, 118-126.	0.8	7
436	Activated fibroblasts in cardiac and cancer fibrosis: An overview of analogies and new potential therapeutic options. <i>Life Sciences</i> , 2023, 321, 121575.	2.0	2
437	Prognostic implications of six-minute walking distance in patients with heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2023, 379, 76-81.	0.8	0
438	The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies. <i>Biomedicines</i> , 2023, 11, 442.	1.4	6
439	Pathophysiological Mechanisms of Cardiac Dysfunction in Transgenic Mice with Viral Myocarditis. <i>Cells</i> , 2023, 12, 550.	1.8	3
440	Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2023, 324, H443-H460.	1.5	6
441	The influence of epigenetics and inflammation on cardiometabolic risks. <i>Seminars in Cell and Developmental Biology</i> , 2024, 154, 175-184.	2.3	3
442	Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2023, 147, 1147-1161.	1.6	35
443	In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4903.	1.8	1
445	Cardiac System during the Aging Process. , 2023, .		3
446	Differences in the Profile of Circulating Immune Cell Subsets in Males with Type 2 Cardiorenal Syndrome versus CKD Patients without Established Cardiovascular Disease. <i>Biomedicines</i> , 2023, 11, 1029.	1.4	1
447	ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts. <i>Circulation Research</i> , 2023, 132, 1110-1126.	2.0	9
448	Multi-omic analysis of the cardiac cellulome defines a vascular contribution to cardiac diastolic dysfunction in obese female mice. <i>Basic Research in Cardiology</i> , 2023, 118, .	2.5	5
449	Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction. <i>Physiology</i> , 0, , .	1.6	1
450	Effects of Sacubitril/Valsartan on cardiac function, blood biochemistry and clinical efficacy in early ventricular remodeling after acute myocardial infarction. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-16.	2.4	1
451	FFAR4 regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome. <i>Journal of Lipid Research</i> , 2023, 64, 100374.	2.0	3
452	Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. <i>Cardiac and Vascular Biology</i> , 2023, , 229-264.	0.2	0
453	Literature Review: Pathophysiology of Heart Failure with Preserved Ejection Fraction. <i>Current Problems in Cardiology</i> , 2023, 48, 101745.	1.1	0

#	ARTICLE	IF	CITATIONS
454	Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review. International Journal of Molecular Sciences, 2023, 24, 7530.	1.8	2
468	Myocardial Metabolic Reprogramming in HFpEF. Journal of Cardiovascular Translational Research, 2024, 17, 121-132.	1.1	1
481	Macrophage-based therapeutic approaches for cardiovascular diseases. Basic Research in Cardiology, 2024, 119, 1-33.	2.5	0